Drug intelligence / Profile preview

EVT0185

Development stage: Preclinical
Lead developer: Espervita Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

EVT0185 is an orally active ATP citrate lyase (ACLY) inhibitor that targets fat metabolism in liver cancer cells, enhancing the immune system's ability to attack them. It was developed by Espervita Therapeutics and shows potential in treating liver cancer by inhibiting lipid synthesis and promoting tumor immunity, particularly through B cells[1][2][3].

Other names: 6-[4-(5-carboxy-5-methyl-hexyl)-phenyl]−2,2-dimethylhexanoic acid

Targets

ACSS2 (Acetyl-coenzyme A synthetase 2)ACLY (ATP-citrate synthase)

Beyond the preview

Go deeper on EVT0185.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVT0185.

Explore the full profile